Lexaria Bioscience Corp (LEXX)

$0.85 +0.02 (1.81%)
Market Cap 16.23M
Revenue (ttm) 460,000.00
Net Income (ttm) -5.80M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,260.87%
Debt to Equity Ratio 0.00
Volume 64,400
Avg Vol 152,198
Day's Range N/A - N/A
Shares Out 19.56M
Stochastic %K 24%
Beta 0.79
Analysts Strong Sell
Price Target $6.00

Company Profile

Lexaria Bioscience Corp. operates as a biotechnology company. It offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. The company's DehydraTECH i...

Industry: Biotechnology
Sector: Healthcare
Phone: 250 765 6424
Address:
740 McCurdy Road, Suite 100, Kelowna, Canada
lem0ntr33
lem0ntr33 Aug. 7 at 6:26 PM
$LEXX wen dilution
0 · Reply
7_Angus_1
7_Angus_1 Aug. 7 at 6:03 PM
$LEXX $LLY Getting a pill form of GLP-1 to work as well as injectables is hard. Improving adverse effects is even harder. Everyone from LLY to $NVO needs Lexx pill technology. LEXX WILL be approached by these heavyweights soon if not already via the MTA. https://www.marketwatch.com/story/pfizers-stock-set-for-worst-day-in-26-years-as-trial-data-from-oral-weight-loss-pill-disappoints-6dd9dda2
0 · Reply
Shubeedoo
Shubeedoo Aug. 7 at 2:52 PM
$LEXX Hope we hold 80 cents
0 · Reply
Shubeedoo
Shubeedoo Aug. 7 at 11:37 AM
$LEXX "Momentum....beating on the door". Have you checked the stock price recently, near a lifetime low
0 · Reply
Bigplayer23
Bigplayer23 Aug. 7 at 11:24 AM
$LEXX If $LEXX Continues Momentum of Marketing…..Pharma companies will be beating on the door https://www.euronews.com/business/2025/08/06/novo-nordisk-keeps-growing-fuelling-hopes-of-a-stock-rebound ”Goldman Sachs acknowledged that uncertainties remain around the GLP-1 and obesity market, as well as Novo Nordisk’s pipeline strength, particularly in light of the eventual semaglutide patent expiry.”
0 · Reply
Bigplayer23
Bigplayer23 Aug. 6 at 6:36 PM
$LEXX Stock Titans identify as a Marketing tool, by the look of things doesn't look like there hasn't been reactions. Things are going in the right direction.
0 · Reply
Makingmillions192
Makingmillions192 Aug. 6 at 6:03 PM
$LEXX Nice news this AM - weekly MACD still confirming bottom is in but MMs will have fun with this for now. Likely we will see more action come September / October
0 · Reply
Bigfin
Bigfin Aug. 6 at 4:09 PM
$LEXX I also saw all the big numbers other 'Lexx-like' companies are getting paid and have to believe we can also get a similar deal. We absolutely need great data and positive outcomes from the studies to get in line for our payday. The thing I find most encouraging is this: if D-Tech actually works to make drugs more efficient, and/or to have fewer negative responses, we will get paid. Facts. The most difficult part is the patience required to stay long. This is made easier by seeing so many companies trying to market their own GLP drugs and to distinguish themselves from the competition. I believe Lexxy will be able to provide the difference maker to these companies in D-Tech. Strong hands lead to fat wallets.
1 · Reply
marginallyinterested
marginallyinterested Aug. 6 at 2:43 PM
$LEXX Thanks for the market update LEXX. Nice to see your competitors are doing well. I look forward to seeing clinical trial data that shows evidence that you really have a "drug absorption/performance enhancer".
0 · Reply
Shubeedoo
Shubeedoo Aug. 6 at 2:41 PM
$LEXX So they paid Stock Titans for an article and so far, have gotten very little reaction.
0 · Reply
Latest News on LEXX
GLP-1 "Arms Race" Broadens to Include Dozens of Companies

Aug 6, 2025, 9:20 AM EDT - 3 days ago

GLP-1 "Arms Race" Broadens to Include Dozens of Companies

Lexaria Provides Positive Interim Results on Partial 8-week Data From Phase 1b, GLP-1-H24-4 Study

Jul 28, 2025, 9:25 AM EDT - 12 days ago

Lexaria Provides Positive Interim Results on Partial 8-week Data From Phase 1b, GLP-1-H24-4 Study

Lexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 Study

Jul 28, 2025, 9:25 AM EDT - 12 days ago

Lexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 Study

Lexaria's DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-Industry

Jul 23, 2025, 9:25 AM EDT - 17 days ago

Lexaria's DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-Industry

Lexaria Reaches Patent Milestone - 50 Patents Now Granted Worldwide

Jun 23, 2025, 9:15 AM EDT - 6 weeks ago

Lexaria Reaches Patent Milestone - 50 Patents Now Granted Worldwide

Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule

Jun 11, 2025, 9:05 AM EDT - 2 months ago

Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule

Lexaria Attending BIO International Convention

Jun 5, 2025, 9:20 AM EDT - 2 months ago

Lexaria Attending BIO International Convention

Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company

May 12, 2025, 9:00 AM EDT - 3 months ago

Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company

Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock

Apr 28, 2025, 4:15 PM EDT - 3 months ago

Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock

Lexaria Announces $2 Million Registered Direct Offering of Common Stock

Apr 25, 2025, 8:00 AM EDT - 3 months ago

Lexaria Announces $2 Million Registered Direct Offering of Common Stock

Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience's Technology

Apr 23, 2025, 9:10 AM EDT - 3 months ago

Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience's Technology

Lexaria Updates its Ongoing Human Study GLP-1-H24-4

Apr 3, 2025, 9:10 AM EDT - 4 months ago

Lexaria Updates its Ongoing Human Study GLP-1-H24-4

Lexaria's Human GLP-1 Study #5 Begins Dosing

Apr 2, 2025, 9:05 AM EDT - 4 months ago

Lexaria's Human GLP-1 Study #5 Begins Dosing

Lexarias' DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly's Injectable Zepbound

Mar 18, 2025, 9:15 AM EDT - 5 months ago

Lexarias' DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly's Injectable Zepbound

Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly's Injectable Zepbound(R)

Mar 18, 2025, 9:15 AM EDT - 5 months ago

Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly's Injectable Zepbound(R)

The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience

Feb 27, 2025, 8:00 AM EST - 5 months ago

The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience

Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm

Feb 24, 2025, 8:00 AM EST - 5 months ago

Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm

Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide

Feb 20, 2025, 8:00 AM EST - 6 months ago

Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide

Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy

Feb 11, 2025, 8:00 AM EST - 6 months ago

Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy

Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway

Feb 6, 2025, 9:40 AM EST - 6 months ago

Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway

Lexaria Releases Annual Letter from the CEO

Jan 30, 2025, 9:15 AM EST - 6 months ago

Lexaria Releases Annual Letter from the CEO

Lexaria's Human GLP-1 Study #5 Receives Independent Review Board Approval

Jan 15, 2025, 9:20 AM EST - 7 months ago

Lexaria's Human GLP-1 Study #5 Receives Independent Review Board Approval

Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound(R)

Jan 14, 2025, 9:10 AM EST - 7 months ago

Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound(R)

Lexaria's Registered GLP-1 Study #4 Begins Dosing

Dec 19, 2024, 9:05 AM EST - 8 months ago

Lexaria's Registered GLP-1 Study #4 Begins Dosing

Lexaria Forms New Scientific Advisory Board

Dec 18, 2024, 9:25 AM EST - 8 months ago

Lexaria Forms New Scientific Advisory Board

Esteemed Harvard Medical School Professor Dr. Michael Gibson Appointed Chief Medical Advisor at Lexaria Bioscience

Dec 17, 2024, 9:10 AM EST - 8 months ago

Esteemed Harvard Medical School Professor Dr. Michael Gibson Appointed Chief Medical Advisor at Lexaria Bioscience

Liraglutide Processed with DehydraTECH to be Studied in Human GLP-1 Study #5

Dec 9, 2024, 9:10 AM EST - 8 months ago

Liraglutide Processed with DehydraTECH to be Studied in Human GLP-1 Study #5

Revolutionizing Healthcare: Lexaria Highlights Expanding Therapeutic Benefits of GLP-1 Drugs

Nov 26, 2024, 9:20 AM EST - 9 months ago

Revolutionizing Healthcare: Lexaria Highlights Expanding Therapeutic Benefits of GLP-1 Drugs

Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled

Nov 25, 2024, 9:00 AM EST - 9 months ago

Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled

ALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria's 12-Week GLP-1, Diabetes Animal Study

Nov 20, 2024, 9:05 AM EST - 9 months ago

ALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria's 12-Week GLP-1, Diabetes Animal Study

Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study

Nov 14, 2024, 9:10 AM EST - 9 months ago

Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study

Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss

Nov 13, 2024, 9:20 AM EST - 9 months ago

Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss

Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments

Nov 7, 2024, 9:15 AM EST - 9 months ago

Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments

Positive Partial 12-Week Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study

Oct 24, 2024, 9:10 AM EDT - 10 months ago

Positive Partial 12-Week Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study

Positive Partial 12-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study

Oct 22, 2024, 9:20 AM EDT - 10 months ago

Positive Partial 12-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study

Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Oct 16, 2024, 4:00 PM EDT - 10 months ago

Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Lexaria Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Oct 15, 2024, 8:25 AM EDT - 10 months ago

Lexaria Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing

Oct 9, 2024, 9:05 AM EDT - 10 months ago

Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing

Lexaria Updates Current GLP-1 Market

Oct 8, 2024, 9:20 AM EDT - 10 months ago

Lexaria Updates Current GLP-1 Market

Lexaria Appoints Michael Shankman as Chief Financial Officer

Oct 1, 2024, 9:25 AM EDT - 11 months ago

Lexaria Appoints Michael Shankman as Chief Financial Officer

Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #3

Sep 27, 2024, 9:20 AM EDT - 11 months ago

Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #3

Lexaria Releases Strategic Letter from the Outgoing CEO

Sep 5, 2024, 10:00 AM EDT - 1 year ago

Lexaria Releases Strategic Letter from the Outgoing CEO

Lexaria Welcomes Industry Veteran as New CEO

Sep 5, 2024, 9:00 AM EDT - 1 year ago

Lexaria Welcomes Industry Veteran as New CEO

Lexaria Enters a Material Transfer Agreement for DehydraTECH Research

Sep 3, 2024, 8:30 AM EDT - 1 year ago

Lexaria Enters a Material Transfer Agreement for DehydraTECH Research

Lexaria's Second GLP-1 Human Pilot Study Shows Zero Adverse Events in DehydraTECH-processed Rybelsus(R) Oral Capsules

Aug 29, 2024, 9:25 AM EDT - 1 year ago

Lexaria's Second GLP-1 Human Pilot Study Shows Zero Adverse Events in DehydraTECH-processed Rybelsus(R) Oral Capsules

First Results from Lexaria's Second GLP-1 Human Pilot Study

Aug 27, 2024, 9:20 AM EDT - 1 year ago

First Results from Lexaria's Second GLP-1 Human Pilot Study

Positive 8-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study

Aug 22, 2024, 9:20 AM EDT - 1 year ago

Positive 8-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study

Positive Interim Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study

Aug 21, 2024, 9:00 AM EDT - 1 year ago

Positive Interim Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study

Positive Results from Lexaria's Molecular Characterization Study

Aug 19, 2024, 9:05 AM EDT - 1 year ago

Positive Results from Lexaria's Molecular Characterization Study

Positive Interim Body Weight Results from Lexaria's Diabetes Animal Study

Jul 17, 2024, 10:30 AM EDT - 1 year ago

Positive Interim Body Weight Results from Lexaria's Diabetes Animal Study

lem0ntr33
lem0ntr33 Aug. 7 at 6:26 PM
$LEXX wen dilution
0 · Reply
7_Angus_1
7_Angus_1 Aug. 7 at 6:03 PM
$LEXX $LLY Getting a pill form of GLP-1 to work as well as injectables is hard. Improving adverse effects is even harder. Everyone from LLY to $NVO needs Lexx pill technology. LEXX WILL be approached by these heavyweights soon if not already via the MTA. https://www.marketwatch.com/story/pfizers-stock-set-for-worst-day-in-26-years-as-trial-data-from-oral-weight-loss-pill-disappoints-6dd9dda2
0 · Reply
Shubeedoo
Shubeedoo Aug. 7 at 2:52 PM
$LEXX Hope we hold 80 cents
0 · Reply
Shubeedoo
Shubeedoo Aug. 7 at 11:37 AM
$LEXX "Momentum....beating on the door". Have you checked the stock price recently, near a lifetime low
0 · Reply
Bigplayer23
Bigplayer23 Aug. 7 at 11:24 AM
$LEXX If $LEXX Continues Momentum of Marketing…..Pharma companies will be beating on the door https://www.euronews.com/business/2025/08/06/novo-nordisk-keeps-growing-fuelling-hopes-of-a-stock-rebound ”Goldman Sachs acknowledged that uncertainties remain around the GLP-1 and obesity market, as well as Novo Nordisk’s pipeline strength, particularly in light of the eventual semaglutide patent expiry.”
0 · Reply
Bigplayer23
Bigplayer23 Aug. 6 at 6:36 PM
$LEXX Stock Titans identify as a Marketing tool, by the look of things doesn't look like there hasn't been reactions. Things are going in the right direction.
0 · Reply
Makingmillions192
Makingmillions192 Aug. 6 at 6:03 PM
$LEXX Nice news this AM - weekly MACD still confirming bottom is in but MMs will have fun with this for now. Likely we will see more action come September / October
0 · Reply
Bigfin
Bigfin Aug. 6 at 4:09 PM
$LEXX I also saw all the big numbers other 'Lexx-like' companies are getting paid and have to believe we can also get a similar deal. We absolutely need great data and positive outcomes from the studies to get in line for our payday. The thing I find most encouraging is this: if D-Tech actually works to make drugs more efficient, and/or to have fewer negative responses, we will get paid. Facts. The most difficult part is the patience required to stay long. This is made easier by seeing so many companies trying to market their own GLP drugs and to distinguish themselves from the competition. I believe Lexxy will be able to provide the difference maker to these companies in D-Tech. Strong hands lead to fat wallets.
1 · Reply
marginallyinterested
marginallyinterested Aug. 6 at 2:43 PM
$LEXX Thanks for the market update LEXX. Nice to see your competitors are doing well. I look forward to seeing clinical trial data that shows evidence that you really have a "drug absorption/performance enhancer".
0 · Reply
Shubeedoo
Shubeedoo Aug. 6 at 2:41 PM
$LEXX So they paid Stock Titans for an article and so far, have gotten very little reaction.
0 · Reply
Bigplayer23
Bigplayer23 Aug. 6 at 1:51 PM
$LEXX https://www.stocktitan.net/news/LEXX/glp-1-arms-race-broadens-to-include-dozens-of-rmom11ye8qzm.html
0 · Reply
stockquote01
stockquote01 Aug. 5 at 7:10 PM
It amazing how low (less than 2M$) the MC of $ONCO stand still. 10% of OCUVEX would worth +-20 millions or 32$ /share... I understand the papers are not signed yet but hey, we're close... https://ir.onconetix.com/onconetix-and-ocuvex-therapeutics-announce-execution-of-definitive-merger-agreement/ $LEXX $SMX $KAPA
1 · Reply
Shubeedoo
Shubeedoo Aug. 5 at 2:24 PM
$LEXX Old news Bigplayer. Where is LEXX on timing now for the 4 open studies, especially the Australia results?
0 · Reply
Bigplayer23
Bigplayer23 Aug. 5 at 2:00 PM
$LEXX
0 · Reply
Shubeedoo
Shubeedoo Aug. 5 at 11:26 AM
$LEXX Australia results will most likely be pushed off into 2026, that's just pharma. Do we trade down to 50 cents and wait? Going to need more cash, so there's more dilution and probably a reverse split again. Who has a different view and it must be realistic?
1 · Reply
cfk113
cfk113 Aug. 4 at 6:27 PM
$LEXX https://www.uniladtech.com/science/news/ozempic-ageing-effect-shocking-new-study-reveals-110295-20250801
0 · Reply
Makingmillions192
Makingmillions192 Aug. 4 at 6:11 PM
$LEXX It’s more likely that LEXX is working towards partnering with the MTA to continue human clinical trials. At that point the cash infusions into LEXX could be enormous. And that’s what we’re betting on in the short term. Medium term 12-24 months there could be a buyout once human trials are fully done. Buy and hold
0 · Reply
Shubeedoo
Shubeedoo Aug. 4 at 2:57 PM
$LEXX IBG at .65??
0 · Reply
ZhaoSonsWealth
ZhaoSonsWealth Aug. 4 at 2:31 PM
IBG has 10x potential Micro float. No dilution. Sitting quietly now but one merger headline could turn this into a full-blown squeeze. SPACs like this don’t stay hidden forever. $YYAI $BFRG $OPGN $LEXX $OPEN
1 · Reply
Shubeedoo
Shubeedoo Aug. 4 at 12:46 PM
$LEXX So what does this week hold?
1 · Reply
form4ai
form4ai Aug. 1 at 10:12 PM
$LEXX my absolute deep analysis boils down to this insider buy. I believe in this secretary. Im all in. (Only down 250 so far) Join https://www.form4.ai/ to get real-time notifications on your phone. Start losing money on insider trades instead of random stocks!
0 · Reply
DudeMcgee
DudeMcgee Aug. 1 at 7:38 PM
$LEXX I must admit that I initially felt uninspired when I had read the interim results of the Phase 1b Human Study #4 Design - GLP-1-H24-4 study. I think I was just wanting results that had superior performance in all areas... results that would make me feel like we are sealing the deal. But, I looked back at the study on the investor deck and refreshed myself to the fact that we still have 2 arms of the study that incorporates the DHT-CBD. I know it is only a Zucker rat study, but remember in the 12 week Animal Study WEIGHT-A24-1, 3 of the DHT-CBD arms outperformed all other arms containing Rybelsus. So my question is this... What happens if, at the end of the Phase 1b Human Study #4 Design - GLP-1-H24-4 study, the CBD arms outperform in all parameters? Would it be big pharma's coming to Jesus moment in terms of CBD? How does MTA PharmaCo treat that info? What would that mean in terms of the value of DHT-CBD formulations in not only the GLP lane, but also its hypertension lane?
0 · Reply